Idenix Pharmaceuticals, Inc. – Product Pipeline
Review – Q1 2011
Reference Code: GMDHC1191CDB
Publication Date: MAY 2011
Idenix Pharmaceuticals, Inc. – Product Pipeline Review – Q1 2011 GMDHC1191CDB / Published MAY 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Idenix Pharmaceuticals, Inc. – Product Pipeline Review
Ta b le o f Co n te n ts
Table of Contents 2
List of Tables 4
List of Figures 4
Idenix Pharmaceuticals, Inc. Snapshot 5
Idenix Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Idenix Pharmaceuticals, Inc. – Research and Development Overview 6
Key Therapeutic Areas 6
Idenix Pharmaceuticals, Inc. – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
Pipeline Products – Combination Treatment Modalities 10
Idenix Pharmaceuticals, Inc. – Pipeline Products Glance 11
Idenix Pharmaceuticals, Inc. Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Idenix Pharmaceuticals, Inc.–Early Stage Pipeline Products 13
Pre-Clinical Products/Combination Treatment Modalities 13
Idenix Pharmaceuticals, Inc. – Drug Profiles 14
IDX184 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Valopicitabine + Pegylated-Interferon 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
IDX320 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
IDX320 + IDX184 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
IDX375 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
IDX102 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
IDX136 20
Product Description 20
Idenix Pharmaceuticals, Inc. – Product Pipeline Review – Q1 2011 GMDHC1191CDB / Published MAY 2011
©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(2)
Idenix Pharmaceuticals, Inc. – Product Pipeline Review
Mechanism of Action 20
R&D Progress 20
IDX316 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
NS5A Inhibitor Program 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Idenix Pharmaceuticals, Inc. – Pipeline Analysis 23
Idenix Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class 23
Idenix Pharmaceuticals, Inc. - Pipeline Products By Target 25
Idenix Pharmaceuticals, Inc. – Pipeline Products by Route of Administration 26
Idenix Pharmaceuticals, Inc. – Pipeline Products by Molecule Type 27
Idenix Pharmaceuticals, Inc. – Recent Pipeline Updates 28
Idenix Pharmaceuticals, Inc. - Dormant Projects 30
Idenix Pharmaceuticals, Inc. - Discontinued Pipeline Products 31
Discontinued Pipeline Product Profiles 31
IDX320 31
Valopicitabine + Pegylated-Interferon 31
Idenix Pharmaceuticals, Inc. – Company Statement 32
Idenix Pharmaceuticals, Inc. – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Financial Deals Landscape 36
Idenix Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2011 36
Idenix Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2011 37
Idenix Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2011 38
Idenix Pharmaceuticals, Inc. Detailed Deal Summary 39
Equity Offering 39
Idenix Pharmaceuticals Completes Public Offering Of $23 Million 39
Idenix Pharmaceuticals Completes Private Placement Of $17 Million 41
Idenix Pharmaceuticals Completes Public Offering Of $145.4 Million 43
Idenix Completes Initial Public Offering Of $64.4 Million 45
Idenix Completes Private Placement Of $75.6 Million 47
Idenix Pharmaceuticals Amends Its Agreement With Novartis Pharma 49
Idenix Pharmaceuticals Signs An Agreement With Metabasis Therapeutics 50
Licensing Agreements 51
GlaxoSmithKline Enters Into Licensing Agreement With Idenix Pharmaceuticals 51
Idenix Enters Into A Licensing Agreement With Novartis Pharma 53